|
|
|
|
| LEADER |
02200nam a2200313 u 4500 |
| 001 |
EB001897167 |
| 003 |
EBX01000000000000001060172 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.)
|h Elektronische Ressource
|b indication : for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
|
| 246 |
3 |
1 |
|a Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Latanoprostene bunod (Vyzulta)
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c July 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 653 |
|
|
|a Glaucoma / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Ocular Hypertension / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Intraocular Pressure / drug effects
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK549613
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that latanoprostene bunod 0.24 mg/ml ophthalmic solution (Vyzulta) be reimbursed for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) only if the following conditions are met : Conditions for Reimbursement : Initiation criteria 1. Patient must be ≥ 18 years 2. Patient must have a documented diagnosis of open-angle glaucoma or ocular hypertensionin one or both eyes. Pricing condition: The cost of treatment with LBN ophthalmic 0.024% solution should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA) or least costly beta-blocker reimbursed for the treatment of open-angle glaucoma or ocular hypertension
|